Emergent BioSolutions Inc
NYSE:EBS
Intrinsic Value
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. [ Read More ]
The intrinsic value of one
EBS
stock under the Base Case scenario is
34.29
USD.
Compared to the current market price of 2.01 USD,
Emergent BioSolutions Inc
is
Undervalued by 94%.
Emergent BioSolutions Inc's market capitalization is 104.9m USD.
EBS stock price is 2.01 USD.
EBS stock price (2.01 USD) is 94% less than its Intrinsic Value (34.29 USD).
EBS. Open DCF Valuation
EBS has upside potential of 154% compared to the average analyst price target.
Open Wall St Estimates
EBS's short-term assets (680m USD) exceed its short-term liabilties (651m USD).
EBS's Revenue has dropped by 6% over the past 12 months.
EBS's Revenue is forecast to fall at a rate of 8% per year over the next 3 years.
EBS has negative Operating Income for the last twelve months.
EBS's long-term assets (2B USD) exceed its long-term liabilties (1B USD).
EBS has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
EBS's ROE (Return on Equity) has significantly decreased in the last 3 years from 30% to -75%.
EBS's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 19% to -10%.
EBS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -10%.
EBS's Revenue has been falling by 12% per year for the last 3 years.
EBS's D/E (Debt to Equity) is very low and is equal to 0.69.
EBS has negative Net Income for the last twelve months.
EBS's ROE (Return on Equity) for the past 12 months is negative and is equal to -75%.
EBS has positive Gross Profit for the last twelve months.
EBS has positive Net Debt. This means that the company has more debt (447m USD) than cash and short-term investments (112m USD).
EBS has negative Free Cash Flow for the last twelve months.
EBS has negative three-year average ROE (Return on Equity): -11%. The company is not efficient at transforming stockholders' equity into net income.
EBS's Altman Z-Score is very low and is equal to 0.2.
EBS doesn't generate enough operating income (-202m USD) to safely cover interest payments on its debt (68m USD).
Fundamental Analysis
Emergent BioSolutions Inc
Balance Sheet Decomposition
Emergent BioSolutions Inc
| Current Assets | 679.5m |
| Cash & Short-Term Investments | 111.7m |
| Receivables | 191m |
| Other Current Assets | 376.8m |
| Non-Current Assets | 1.1B |
| PP&E | 399m |
| Intangibles | 566.6m |
| Other Non-Current Assets | 178.1m |
| Current Liabilities | 651.3m |
| Accounts Payable | 112.2m |
| Accrued Liabilities | 96.2m |
| Other Current Liabilities | 442.9m |
| Non-Current Liabilities | 522.6m |
| Long-Term Debt | 446.5m |
| Other Non-Current Liabilities | 76.1m |
Earnings Waterfall
Emergent BioSolutions Inc
|
Revenue
|
1B
USD
|
|
Cost of Revenue
|
-705.4m
USD
|
|
Gross Profit
|
343.9m
USD
|
|
Operating Expenses
|
-545.4m
USD
|
|
Operating Income
|
-201.5m
USD
|
|
Other Expenses
|
-559m
USD
|
|
Net Income
|
-760.5m
USD
|
Free Cash Flow Analysis
Emergent BioSolutions Inc
EBS Profitability Score
Profitability Due Diligence
Emergent BioSolutions Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Emergent BioSolutions Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
EBS Solvency Score
Solvency Due Diligence
Emergent BioSolutions Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
Emergent BioSolutions Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EBS Price Targets Summary
Emergent BioSolutions Inc
According to Wall Street analysts, the average 1-year price target for
EBS
is 5.1 USD
with a low forecast of 5.05 USD and a high forecast of 5.25 USD.
Ownership
EBS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
EBS Price
Emergent BioSolutions Inc
| Average Annual Return | -12.69% |
| Standard Deviation of Annual Returns | 64.72% |
| Max Drawdown | -99% |
| Market Capitalization | 104.9m USD |
| Shares Outstanding | 52 203 400 |
| Percentage of Shares Shorted | 18.02% |
EBS News
Last Important Events
Emergent BioSolutions Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Emergent BioSolutions Inc
Company Profile
Emergent BioSolutions Inc
Country
Industry
Market Cap
Dividend Yield
Description
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.
You don't have any saved screeners yet
